{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:44:53Z","timestamp":1759495493935,"version":"3.40.5"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.therap.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:22:16Z","timestamp":1716488536000},"page":"699-708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["How could proton pump inhibitors de-prescription be managed in geriatric long-term care?"],"prefix":"10.1016","volume":"79","author":[{"given":"Elma","family":"Mati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Mioux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Ollagnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziza","family":"Waissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nacera","family":"Benzerdjeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karima","family":"Messaoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blandine","family":"De La Gastine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fay\u00e7al","family":"Aouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabiha","family":"Ahmine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Leperre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0467-4382","authenticated-orcid":false,"given":"Nathalie","family":"Bleyzac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.05.002_bib0270","unstructured":"French National Agency for the Safety of Medicinal Products (ANSM). Use of proton pump inhibitors (PPIs) observational study from SNDS data, France, 2015. 2018.https:\/\/www.epi-phare.fr\/app\/uploads\/2020\/04\/EPI-PHARE_2018_utilisation_IPP.pdf. [Accessed 13 May 2024 (78 pp.)]"},{"key":"10.1016\/j.therap.2024.05.002_bib0275","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2024.05.002_bib0280","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/ijerph16091571","article-title":"Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved","volume":"16","author":"Thong","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2024.05.002_bib0285","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10654-016-0136-8","article-title":"Proton pump inhibitors and gastroenteritis","volume":"31","author":"Hassing","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.therap.2024.05.002_bib0290","first-page":"11","article-title":"Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection: systematic review: proton pump inhibitors and bacterial diarrhoea","volume":"34","author":"Bavish","year":"2011","journal-title":"Alim Pharmacol Ther"},{"key":"10.1016\/j.therap.2024.05.002_bib0295","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.3748\/wjg.v23.i35.6500","article-title":"Proton pump inhibitors therapy and risk of C.\u00a0difficile infection: systematic review and meta-analysis","volume":"23","author":"Trifan","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.therap.2024.05.002_bib0300","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1001\/jama.294.23.2989","article-title":"Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease","volume":"294","author":"Dial","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2024.05.002_bib0305","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/bmj.312.7028.414","article-title":"Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study","volume":"312","author":"Neal","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2024.05.002_bib0310","doi-asserted-by":"crossref","first-page":"20873","DOI":"10.2807\/1560-7917.ES2014.19.32.20873","article-title":"Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use\u00a0\u2013\u00a0an ecological study","volume":"19","author":"Bouwknegt","year":"2014","journal-title":"Euro Surveill"},{"key":"10.1016\/j.therap.2024.05.002_bib0315","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/cid\/ciu628","article-title":"Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case-control study","volume":"59","author":"Wu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2024.05.002_bib0320","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/jgs.15385","article-title":"Proton-pump inhibitors and long-term risk of community-acquired pneumonia in older adults","volume":"66","author":"Zirk-Sadowski","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2024.05.002_bib0325","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s43440-021-00263-x","article-title":"Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis","volume":"73","author":"Pranata","year":"2021","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.therap.2024.05.002_bib0330","doi-asserted-by":"crossref","first-page":"637885","DOI":"10.3389\/fmed.2021.637885","article-title":"Acid pH increases SARS-CoV-2 infection and the risk of death by COVID-19","volume":"8","author":"Jimenez","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.therap.2024.05.002_bib0335","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13195-015-0164-8","article-title":"Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software","volume":"27","author":"Akter","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.therap.2024.05.002_bib0340","doi-asserted-by":"crossref","first-page":"462","DOI":"10.23736\/S2724-6051.21.04116-3","article-title":"Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease","volume":"73","author":"Vengrus","year":"2021","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.therap.2024.05.002_bib0345","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11894-010-0141-0","article-title":"Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium","volume":"12","author":"Ito","year":"2010","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.therap.2024.05.002_bib0350","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/imj.12697","article-title":"Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis","volume":"45","author":"Jung","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.therap.2024.05.002_bib0355","unstructured":"French National Authority for Health (HAS). Proper use of the drug proton pump inhibitors in adults. 2009. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2009-06\/ipp_adulte_juin_2009.pdf. [Accessed 13 May 2024]"},{"key":"10.1016\/j.therap.2024.05.002_bib0360","unstructured":"French Transparency Commission. Evaluation report on proton pump inhibitors (proprietary and generic). 2020. https:\/\/www.hassante.fr\/upload\/docs\/application\/pdf\/2020-11\/rapport_reevaluation_ipp_avisdef_cteval493.pdf. [Accessed 13 May 2024]"},{"key":"10.1016\/j.therap.2024.05.002_bib0365","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.therap.2024.05.002_bib0370","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.therap.2024.05.002_bib0375","unstructured":"ANSM. Summary of product characteristics. Esom\u00e9prazole 2012. http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0206444.htm. [Accessed 13 May 2024]"},{"key":"10.1016\/j.therap.2024.05.002_bib0380","unstructured":"ANSM. Summary of product characteristics. Lansoprazole 2013. http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0225901.htm. [Accessed 13 May 2024]"},{"key":"10.1016\/j.therap.2024.05.002_bib0385","unstructured":"ANSM. Summary of product characteristics. Omeprazole 2014. http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0240539.htm. [Accessed 13 May 2024]"},{"key":"10.1016\/j.therap.2024.05.002_bib0390","unstructured":"ANSM. Summary of product characteristics. Pantoprazole 2011. http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0194918.htm. [Accessed 13 May 2024]"},{"key":"10.1016\/j.therap.2024.05.002_bib0395","unstructured":"ANSM. Summary of product characteristics. Rab\u00e9prazole 2013. http:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/rcp\/R0218775.htm. [Accessed 13 May 2024]"},{"key":"10.1016\/j.therap.2024.05.002_bib0400","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/1060028018759747","article-title":"Implementation of proton pump inhibitor deprescription protocol in geriatric residents","volume":"52","author":"Avraham","year":"2018","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.therap.2024.05.002_bib0405","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.sger.2015.09.010","article-title":"Prescription for proton pump inhibitors in geriatrics","volume":"116","author":"Schonheit","year":"2015","journal-title":"Soins Gerontol"},{"key":"10.1016\/j.therap.2024.05.002_bib0410","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.therap.2017.06.003","article-title":"Evaluation of the prescription of proton pump inhibitors in persons aged 75 years and older in a geriatric acute-care unit","volume":"72","author":"Dipanda","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.05.002_bib0415","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.sapharm.2016.02.012","article-title":"Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US","volume":"13","author":"Rane","year":"2017","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.therap.2024.05.002_bib0420","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.therap.2020.03.002","article-title":"Use and management of proton pump inhibitors: an observational study","volume":"75","author":"Gramont","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.05.002_bib0425","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharma.2020.01.001","article-title":"Reassessment of inappropriate prescriptions of proton pump inhibitors in elderly in-patients: it's time to take action","volume":"78","author":"Nowbahari","year":"2020","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.therap.2024.05.002_bib0430","first-page":"383","article-title":"Appropriate proton pump inhibitors use in elderly outpatients according to recommendations","volume":"14","author":"Schonheit","year":"2016","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"key":"10.1016\/j.therap.2024.05.002_bib0435","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.amjopharm.2008.12.001","article-title":"Appropriate proton pump inhibitor use among older adults: a retrospective chart review","volume":"6","author":"George","year":"2008","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.therap.2024.05.002_bib0440","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ejim.2010.11.009","article-title":"Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly","volume":"22","author":"Pasina","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.therap.2024.05.002_bib0445","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.revmed.2015.04.014","article-title":"Survey of the prescriptions of proton pump inhibitors in patients admitted in an internal medicine ward: how is the compliance to the French guidelines?","volume":"36","author":"Sauvaget","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.therap.2024.05.002_bib0450","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0016-5085(99)70118-6","article-title":"Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status","volume":"116","author":"Gillen","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.therap.2024.05.002_bib0455","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.3390\/ijms20215469","article-title":"Problems associated with deprescribing of proton pump inhibitors","volume":"20","author":"Helgadottir","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.therap.2024.05.002_bib0460","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.39.5.649","article-title":"Marked increase in gastric acid secretory capacity after omeprazole treatment","volume":"39","author":"Waldum","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.therap.2024.05.002_bib0465","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2036.2004.02271.x","article-title":"Rebound acid hypersecretion after long-term inhibition of gastric acid secretion","volume":"21","author":"Fossmark","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.therap.2024.05.002_bib0470","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2009.03.058","article-title":"Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy","volume":"137","author":"Reimer","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.therap.2024.05.002_bib0475","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/ajg.2010.81","article-title":"Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial","volume":"105","author":"Niklasson","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.therap.2024.05.002_bib0480","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000236025","article-title":"Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial","volume":"81","author":"van der Velden","year":"2010","journal-title":"Digestion"},{"key":"10.1016\/j.therap.2024.05.002_bib0485","first-page":"354","article-title":"Deprescribing proton pump inhibitors: evidence-based clinical practice guideline","volume":"63","author":"Farrell","year":"2017","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.therap.2024.05.002_bib0490","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/fampra\/cmu050","article-title":"Strategies for discontinuation of proton pump inhibitors: a systematic review","volume":"31","author":"Haastrup","year":"2014","journal-title":"Fam Pract"},{"key":"10.1016\/j.therap.2024.05.002_bib0495","first-page":"32","article-title":"R\u00e9vision de l\u2019ordonnance chez les sujets \u00e2g\u00e9s fragiles","volume":"3","author":"Beuscart","year":"2020","journal-title":"Corresp Med Cognit Vieil"},{"key":"10.1016\/j.therap.2024.05.002_bib0500","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"67","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2024.05.002_bib0505","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.revmed.2008.08.010","article-title":"Potentially inappropriate medications in the elderly: a list adapted to French medical practice","volume":"30","author":"Laroche","year":"2009","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.therap.2024.05.002_bib0510","first-page":"323","article-title":"STOPP\/START.v2 criteria: adaptation into French language","volume":"15","author":"Lang","year":"2015","journal-title":"Neurol Psychiatr Geriatr"},{"key":"10.1016\/j.therap.2024.05.002_bib0515","unstructured":"French National Authority for Health. Prescribing in the elderly Brochure PMSA program. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/traceur_has_fichesynth_sujetage.pdf. [Accessed 13 May 2024]."},{"key":"10.1016\/j.therap.2024.05.002_bib0520","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/jgs.12037","article-title":"Drug-related readmissions to medical units of older adults discharged from acute geriatric units: results of the optimization of medication in AGEd multicenter randomized controlled trial","volume":"61","author":"Bonnet-Zamponi","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2024.05.002_bib0525","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/j.1532-5415.2011.03628.x","article-title":"A new multimodal geriatric discharge-planning intervention to prevent emergency visits and rehospitalizations of older adults: the optimization of medication in AGEd multicenter randomized controlled trial","volume":"59","author":"Legrain","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.therap.2024.05.002_bib0530","first-page":"7","article-title":"L\u2019inertie clinique, un conflit entre deux logiques","volume":"10","author":"Reach","year":"2012","journal-title":"PSN"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T13:55:04Z","timestamp":1732370104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0040595724000647"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.05.002","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How could proton pump inhibitors de-prescription be managed in geriatric long-term care?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}